Journal article

HIGH-DOSE BUSULPHAN/CYCLOPHOSPHAMIDE FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION IS ASSOCIATED WITH MINIMAL NONHEMATOPOIETIC TOXICITY

MA ROSENTHAL, AP GRIGG, WP SHERIDAN

LEUKEMIA & LYMPHOMA | HARWOOD ACAD PUBL GMBH | Published : 1994

Abstract

We retrospectively reviewed the regimen-related toxicity associated with busulphan (1 mg/kg orally QID days -7 to -4) and cyclophosphamide (60 mg/kg IV days -3 and -2) (Bu/Cy) chemotherapy in 69 consecutive patients who underwent autologous bone marrow transplantation (ABMT). Twenty-four patients received bone marrow (BM) alone, 22 received BM plus post-transplant granulocyte-colony stimulating factor (G-CSF) and 23 received peripheral blood progenitor cells (PBPC) +/- BM plus post-transplant G-CSF. Toxicity was scored using the criteria of Bearman. Grade II and III toxicities included mucosa (38%), liver (8%), central nervous system (5%), kidney (5%), heart (3%), pericardium (2%), bladder (..

View full abstract